Brought to you by 
Avalanche closes $56mm Series B to support wet AMD candidate AVA101
30 May 2014
Executive Summary
Avalanche Biotechnologies Inc. (gene therapeutics for ophthalmic diseases) completed a $56mm Series B round. A total of 45 investors participated, including new shareholders Venrock (lead), Deerfield, Adage Capital Management, Redmile Group, Rock Springs Capital, Sabby Capital, a Cowen & Co. affiliate, and undisclosed blue chip health care funds, along with returning backers. Cowen & Co. was the placement agent.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Avalanche closes $56mm Series B to support wet AMD candidate AVA101
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice